TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Beyondspring Inc.
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path

BeyondSpring presented Phase 3 DUBLIN-3 trial results showing Plinabulin plus docetaxel improved overall survival in Asian patients with EGFR wild-type non-small cell lung cancer, with reduced neutropenia and promising survival rates.

Insights
BYSI   positive

Presented promising clinical trial results demonstrating survival benefit and safety improvements for their lead drug Plinabulin in lung cancer treatment